USFDA to review Teva and Celltrion's cancer biosimilar drug
JERUSALEM: Teva Pharmaceutical Industries and South Korea's Celltrion said the U.S. Food and Drug Administration has accepted for review a biologics application for a biosimilar drug to treat breast cancer.
The companies said the FDA has accepted the filing of CT-P6 with regulatory action expected in the first half of 2018.
CT-P6, already approved by the Korean Ministry of Food and Drug Safety, is a biosimilar -- a copy of a biotech drug -- to Roche Holding's breast cancer and gastric cancer treatment Herceptin. Earlier this month, an advisory panel to the FDA recommended approval of a Herceptin biosimilar from Mylan and Biocon.
Sales of Herceptin were 3.54 billion Swiss francs ($3.65 billion) in the first half of 2017.
Celltrion and Teva last year entered into an exclusive partnership to commercialize CT-P6 as well as CT-P10 -- a biosimilar to Roche's blockbuster biotech cancer drug Rituxan -- in the United States and Canada. The FDA is also reviewing a Biologics License Application for CT-P10, with action expected in the first half of 2018.
($1 = 0.9687 Swiss francs)
(Reporting by Steven Scheer)
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd